NEW YORK (September 9, 2015) –Forbes launched its Health, Science & Innovation September 28 magazine issue, featuring the 30-year-old behind biotech’s biggest IPO, Vivek Ramaswamy, on the cover. Cover story Boy in the Bubble (p. 80) details how a former hedge fund trader has become the wonder kid of biotech. Ramaswamy says he has found an ingenious new model for drug development using Wall Street tactics and is engineering several deals that rescue drugs forgotten by the big firms. He bought an Alzheimer’s drug from a large pharmaceutical company for $5 million less than a year ago and built a publicly traded company around it that is now worth more than $1 billion. Some think that’s simply a sign that there is a bubble in biotechnology stocks, but Forbes explains Ramaswamy’s methods and reveals his story for the first time.
